September 22, 2020— A recent Wall Street Journal opinion piece by a pharmaceutical industry consultant resurfaces claims that statutory discounts for safety-net hospitals, health centers, and clinics are forcing drug companies to hike their prices. Drug manufacturers are using this false notion as a pretext for urging program cutbacks in the guise of “reforms” and for refusing … [Read more...]
Drug Industry Consultant Paints Incomplete Picture of 340B
May 14, 2019– Drug-industry consultant Adam Fein has released his annual analysis of the 340B program, painting an incomplete picture of the size and scope of the program. Fein claims in his Drug Channels blog that the 340B program “accounts for at least 7-to-8 percent of the total U.S. drug market […] yet hospitals’ charity care has dropped amid 340B program’s growth.” Not … [Read more...]
Blogger’s Misleading 340B Numbers
May 11, 2018 – In a recent Drug Channels blog post, Adam Fein reports that 340B spending has reached $19.3 billion in 2017, and claims that 340B is “a significant and growing part of the [pharmaceutical] industry.” However, that conclusion is not supported by the facts. In fact, Fein’s own numbers suggest a different narrative regarding the size and impact of the 340B program … [Read more...]